NPS Pharmaceuticals, Inc.

Promotion agreement announced for Kineret rheumatoid arthritis therapy

Published in Physician Law Weekly, September 8th, 2004

NPS Pharmaceuticals, Inc., (NPSP) has executed an agreement with Amgen Inc. to promote Kineret, a biologic therapy for the treatment of moderate to severe rheumatoid arthritis (RA), in the United States.

Kineret could be an excellent alternative when an anti-TNF therapy provides an inadequate response. The agreement accelerates the creation of a sales and marketing organization by NPS in preparation for launching the company's investigational drug candidate, PREOS, which is being studied for the treatment of osteoporosis.

It also provides dedicated promotional support for Kineret, creating a mutually beneficial arrangement for NPS and Amgen on the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2004-09-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry